Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Efgartigimod PH20 SC Prefilled Syringe vs Vial in Healthy Adults
NCT05817435Phase 1Completed
- Sponsor
- argenx
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by argenx. Primary endpoints: Maximum Observed Serum Concentration up to 29 days and Area Under the Concentration-Time Curve From Time Zero to Infinity up to 29 days. Started Mar 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT05817435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817435.